These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32629362)

  • 1. The 5-Ws of immunotherapy in head and neck cancer.
    Botticelli A; Mezi S; Pomati G; Cerbelli B; Di Rocco C; Amirhassankhani S; Sirgiovanni G; Occhipinti M; Napoli V; Emiliani A; Mazzuca F; Tomao S; Nuti M; Marchetti P
    Crit Rev Oncol Hematol; 2020 Sep; 153():103041. PubMed ID: 32629362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
    Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
    Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
    Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
    Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Moskovitz J; Moy J; Ferris RL
    Curr Oncol Rep; 2018 Mar; 20(2):22. PubMed ID: 29502288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
    Mei Z; Huang J; Qiao B; Lam AK
    Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["Immunotherapy in head and neck squamous cell carcinoma"].
    Marret G; Borcoman É; Le Tourneau C
    Rev Prat; 2021 Apr; 71(4):396-399. PubMed ID: 34161005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
    Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
    Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients.
    Botticelli A; Cirillo A; d'Amati G; Di Gioia C; Corsi A; Della Rocca C; Santini D; Carletti R; Pisano A; Polimeni A; De Vincentiis M; Valentini V; di Cristofano C; Romeo U; Cerbelli E; Messineo D; De Felice F; Leopizzi M; Cerbelli B
    Pathol Res Pract; 2024 Aug; 260():155415. PubMed ID: 38996615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
    Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
    Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
    Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
    Yu Y; Lee NY
    Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.